SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases

To explore the efficacy and safety of stereotactic body radiation therapy (SBRT) combined with PD-1 monoclonal antibody in the treatment of unresectable colorectal cancer liver metastasis through a prospective study, providing high-level evidence-based medical evidence for the use of SBRT combined with PD-1 inhibitors in the treatment of unresectable colorectal cancer liver metastasis.

Trial Details

NCT ID
NCT06794086
Phase
PHASE3
Sponsor
Jun Huang
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Stereotactic body radiation therapy
  • PD-1 Monoclonal Antibody
  • Chemotherapy
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Written informed consent, voluntarily signed and dated by the subject, must be obtained in accordance with regulatory and institutional guidelines …
  • Patients with pMMR/MSS colorectal adenocarcinoma;
  • Age 18-75 years;
  • Patients with histologically or cytologically confirmed colorectal cancer liver metastasis, with or without extrahepatic oligometastatic lesions, w…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →